Development of Novel PROTAC RAD51 Degraders as Enhancers of DNA Damage Response for Hepatocellular Carcinoma Treatment - PubMed
3 months ago
- #Hepatocellular Carcinoma
- #PROTAC
- #RAD51
- Development of first-in-class PROTACs targeting RAD51 for hepatocellular carcinoma treatment.
- SZU305 (15b) shows potent RAD51 degradation and antiproliferative effects in liver cancer cell lines.
- Mechanism involves reduced HR efficiency and impaired DNA damage repair, enhancing chemoradiation sensitivity.
- In vivo, SZU305 exhibits strong antitumor activity, especially when combined with sorafenib or irradiation.
- RAD51 degradation presents a novel strategy to overcome drug resistance in liver cancer.